Risperidone controlled release - Luye Pharma Group

Drug Profile

Risperidone controlled release - Luye Pharma Group

Alternative Names: LY-03004; Risperidone ER microspheres - Luye Pharma Group

Latest Information Update: 03 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Luye Pharma Group
  • Class Antineoplastics; Antipsychotics; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Schizoaffective disorder; Schizophrenia

Most Recent Events

  • 31 Aug 2016 Luye Pharma announces intention to submit NDA to the US FDA
  • 31 Aug 2016 Luye Pharma plans a phase I trial for Schizophrenia in Europe
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Schizoaffective-disorder in USA (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top